|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
04.02.26 - 14:33
|
Veru to Report Fiscal 2026 First Quarter Financial Results on February 11th (GlobeNewswire EN)
|
|
|
MIAMI, FL, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced it will host a conference call and audio webcast on Wednesday, February 11, 2026, at 8:00 a.m. ET to discuss its fiscal 2026 first quarter financial results and to provide a business update....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.12.25 - 14:33
|
Veru to Report Fiscal Year 2025 Financial Results on December 17th (GlobeNewswire EN)
|
|
|
MIAMI, FL, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced it will host a conference call and audio webcast on Wednesday, December 17, 2025, at 8:00 a.m. ET to discuss its fiscal year 2025 financial results and to provide a business update....
|
|
|
04.12.25 - 14:33
|
Veru to Present at The Society on Sarcopenia, Cachexia, and Wasting Disorders 18th International Conference and Regulatory and Clinical Trials Update Regulatory Workshop (GlobeNewswire EN)
|
|
|
MIAMI, FL, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced multiple presentations at The Society on Sarcopenia, Cachexia, and Wasting Disorders (SCWD) 18th International Conference, and the SCWD's Regulatory and Clinical Trials Update Regulatory Workshop, both in Rome, Italy....
|
|
|
31.10.25 - 13:33
|
Veru to Present Two Abstracts at ObesityWeek 2025 (GlobeNewswire EN)
|
|
|
MIAMI, FL, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced the presentation of two abstracts at ObesityWeek 2025 taking place November 4-7, 2025, in Atlanta, Georgia....
|
|
|
|
|
|
|
29.10.25 - 21:06
|
Veru Announces Proposed Public Offering (GlobeNewswire EN)
|
|
|
MIAMI, FL, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, announced today that it has commenced an underwritten public offering of shares of its common stock (or pre-funded warrants to purchase its common stock in lieu thereof) and in either case, accompanying Series A warrants and Series B warrants to purchase shares of its common stock. All securities to be sold in the proposed public offering will be offered by Veru. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering....
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
